Seelos Therapeutics has recently shared promising findings from their latest preclinical study involving SLS-005, a potential treatment for aggressive Alzheimer’s disease. The study utilized older non-human primates and induced tauopathy through bilateral AAV-induced tau overexpression. The primates were divided into three groups: one group received weekly administrations of SLS-005, another group received a single administration of SLS-009, and the last group served as the control.

In a preliminary analysis, the non-human primates that received SLS-005 demonstrated a remarkable 46% reduction in tau protein levels and an 18% reduction in NfL (neurofilament light chain), a protein biomarker. It is worth noting that NfL is a non-specific biomarker associated with various neurodegenerative conditions, including Alzheimer’s, multiple sclerosis, and amyotrophic lateral sclerosis (ALS).

SLS-005 has exhibited its potential to decrease the aggregation of misfolded proteins and the accumulation of pathologic material in animal models of diseases characterized by abnormal cellular protein aggregation or the storage of pathologic material. Furthermore, Seelos Therapeutics is eagerly awaiting the release of top-line data from the SLS-005 registrational Phase 2/3 trial in ALS, which is part of the HEALEY ALS Platform Trial conducted by Harvard Medical School at Massachusetts General Hospital. This data is expected to be made available in the fourth quarter of 2023.

On a different note, Seelos Therapeutics recently concluded the second part of their Phase 2 study involving SLS-002, an intranasal racemic ketamine, as a potential treatment for Acute Suicidal Ideation and Behavior in adults with Major Depressive Disorder. Unfortunately, the study did not meet its pre-defined primary endpoint.

As of September 27, 2023, Seelos Therapeutics’ Stock, symbolized by SEEL, has experienced a notable increase of 13.50%, reaching a value of $0.20.

SEEL Stock Performance on September 27, 2023: Stable with Lower Trading Volume and Positive Trend in Earnings

SEEL stock experienced a relatively stable performance on September 27, 2023. The stock opened at the same price as the previous close, indicating no significant change in value. Throughout the day, the stock fluctuated within a narrow range, reaching a high of $0.21 and a low of $0.18. The trading volume for the day was 828,771 shares, which is lower than the average volume of 2,423,042 shares over the past three months.

SEEL’s market capitalization stands at $20.1 million, reflecting the total value of all its outstanding shares. The company’s earnings growth in the previous year was +4.84%, indicating a positive trend.

The P/E ratio, which compares a company’s stock price to its earnings per share, is listed as NM (not meaningful), suggesting that SEEL may not have positive earnings. The Price/Sales and Price/Book ratios are also not provided, making it difficult to assess the stock’s valuation.

In comparison to other stocks in the Health Technology sector, SEEL’s performance on September 27, 2023, was relatively weaker. NCNANuCana PLC and MDNAMedicenna Therapeuti… both experienced negative changes in their stock prices, with decreases of 7.69% and 5.72%, respectively. On the other hand, FBRXForte Biosciences In… witnessed a slight increase of 1.19%.

SEEL’s next reporting date is scheduled for November 3, 2023. The EPS forecast for this quarter is -$0.08, indicating a projected loss.

SEEL operates in the Biotechnology industry and is headquartered in New York, New York.

Investors will need to closely monitor the company’s upcoming financial reports and earnings forecasts to gain a better understanding of its future prospects.

Seelos Therapeutics Inc (SEEL) Stock Surges on Optimistic Price Forecasts: Potential +875.61% Increase

Seelos Therapeutics Inc (SEEL) experienced a surge in stock performance on September 27, 2023, following optimistic price forecasts from analysts. The 12-month price forecasts indicate a potential increase of +875.61% from the last recorded price of $0.21. Four investment analysts have recommended buying stock in Seelos Therapeutics Inc, indicating confidence in the company’s future prospects. Seelos Therapeutics Inc focuses on developing therapies for central nervous system disorders such as Parkinson’s disease, ALS, and Sanfilippo syndrome. The company’s pipeline of potential therapies has shown promise in clinical trials, and it has a strong financial position. Despite a current quarter loss, investors are optimistic about the company’s long-term potential. Seelos Therapeutics Inc is expected to release its next earnings report on November 3. While investing in any stock carries risks, Seelos Therapeutics Inc may be an attractive opportunity for investors in the biopharmaceutical sector. However, investors should conduct their due diligence and consider their risk tolerance before making any investment decisions.

The post Seelos Therapeutics Shares Promising Findings for Potential Alzheimers Treatment SLS005 and Updates on Other Clinical Trials appeared first on Best Stocks.